ReviewCurrent medicinal chemistry2025
The Markers Auxiliary in Distinguishing Between Nodal Nevi and Melanoma Metastases.
Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Using Disease Models for Mechanistic Studies: Special Focus on Gene Editing.Current medicinal chemistry · 2026Article
- Epigenetics of Malignant Melanoma: Mechanisms, Diagnostic Approaches and Therapeutic Applications.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nodal nevus (NN) and melanoma metastasis (MM) have distinct biological and prognostic significance. They are characterized by different cytomorphological features and varying intranodal localization. However, in some cases, distinguishing them in standard hematoxylin and eosin-stained specimens can be challenging. The aim of this review is to evaluate the usefulness of markers in the diagnosis of NN and MM. The expression of selected markers in NN and MM was examined immunohistochemically in 27 studies. The frequency of HMB-45 and PRAME staining was significantly higher, while p16 was lower in MM than in NN. A slight increase of Ki-67 and decrease of 5- hmC expression in MM compared to NN were also observed. Meanwhile, staining of Melan-A/Mart-1, S-100, and SOX-10 was similar in NN and MM. However, none of the markers applied was completely specific for melanocytes. Although PRAME proved to have the strongest diagnostic potential, it was also detectable in other cell types, especially in lymphocytes and some breast cancers. Immunohistochemical staining of PRAME, HMB-45, and p16 may aid the diagnosis of NN and MM. Ki-67 and 5-hmC may also be of promising significance, whereas the expression of Melan-A/Mart-1, S-100, and SOX-10 does not allow distinguishing NN from MM.
Indexed as
Identifiers
40511655What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.